Balaxi Pharmaceuticals Limited · NSE:BALAXI
Balaxi Pharmaceuticals — H1FY21 Earnings Presentation
48 slides from Balaxi Pharmaceuticals's earnings presentation, Oct 12, 2020
Slide 1: Balaxi Pharmaceuticals Limited
Balaxi Pharmaceuticals Limited To 12" October, 2020 Listing Department, National Stock Exchange of India Limited Exchange Plaza, Plot No C/1, G Block, BKC, Bandra (E), Mumbai-400051 Stock Code: BALAXI Sub: Investor Presentation Dear Sir/Madam, We hereby attach the Investor Presentation issued by the
Slide 2: Investor Presentation
Page - 01 B A L A X I P H A R M A C E U T I C A LS L I M I T E D INVESTOR PRESENTATION
Slide 3: Disclaimer
Page - 02 B A L A X I P H A R M A C E U T I C A LS L I M I T E D Disclaimer This presentation and the following discussion may contain “forward-looking statements” by “Balaxi Pharmaceuticals Limited” that are not historical in nature. Such forward-looking statements are subject to certain risks and
Slide 4: Q2 & H1FY21 Result Highlights
Page - 03 » Q2 & H1FY21 Result Highlights » Business Strategy » Industry & Outlook » Business Overview » Financial Highlights INVESTOR B A L A X I P H A R M A C E U T I C A LS L I M I T E D PRESENTATION Q2 & H1FY21 RESULT HIGHLIGHTS
Slide 5: Quick Overview
Page - 04 Q2 & H1FY21: Quick Overview Revenue EBITDA PAT Q2FY21 - 603 Mn Q2FY21 - 103 Mn Q2FY21 - 101 Mn H1FY21 - 1,124 Mn H1FY21 - 193 Mn H1FY21 - 188 Mn Q2FY21 - 29:71 Pharmaceutical Business Pharmaceutical Business H1FY21 - 24:76 contributes 63% of Revenue contributes 73% of EBITDA (Branded:Gener
Slide 6: Consolidated Financial Highlights
Page - 05 Q2 & H1FY21: Consolidated Financial Highlights In INR Mn Revenue EBITDA & EBITDA Margin PAT & PAT Margin 1,124 17.1% 16.8% 17.2% 16.7% 193 188 603 103 101 Q2 FY21 H1 FY21 Q2 FY21 H1 FY21 Q2 FY21 H1 FY21
Slide 7: Consolidated Profit and Loss Statement
Page - 06 Consolidated Profit and Loss Statement Particulars (In INR Mn) Q2 FY21 Q1FY21 QoQ Growth % H1 FY21 Revenue From Operations 603 521 16% 1,124 Other Income 16 15 4% 31 Total Income 619 536 16% 1,155 COGS 455 392 16% 848 Gross Profit 148 128 15% 276 Gross Margin % 24.5% 24.6% -10 bps 24.6% Em
Slide 8: Consolidated Balancesheet
Page - 07 Consolidated Balancesheet Particulars (In INR Mn) H1FY21 Particulars (In INR Mn) H1FY21 Shareholder's Funds 4,650 Non-Current Assets 267 Equity Share Capital 1,000 Fixed Assets – Tangible & Intangible 168 Reserves & Surplus 3,650 CWIP & Intangibles under development - Minority Interest - O
Slide 9: Segment Revenue Breakup
Page - 08 Segment Revenue Breakup Revenue Mix % (Q2FY21) Revenue Mix % (H1FY21) 29% 27% 64% 10% 63% 7% Pharmaceutical Branded Consumer Products Ancillary Pharmaceutical Branded Consumer Products Ancillary
Slide 10: Pharmaceutical Business Financial Highlights
Page - 09 Q2 & H1FY21: Pharmaceutical Business Financial Highlights In INR Mn Revenue EBITDA & EBITDA Margin PAT & PAT Margin 706 19.5% 19.8% 15.9% 16.1% 140 114 385 75 61 Q2 FY21 H1 FY21 Q2 FY21 H1 FY21 Q2 FY21 H1 FY21
Slide 11: Ancillary Business Financial Highlights
Page - 10 Q2 & H1FY21: Ancillary Business Financial Highlights In INR Mn Revenue EBITDA & EBITDA Margin PAT & PAT Margin 308 12.5% 12.3% 12.3% 12.2% 38 38 177 22 22 Q2 FY21 H1 FY21 Q2 FY21 H1 FY21 Q2 FY21 H1 FY21
Slide 12: Branded Consumer Products Business Financial Highlights
Page - 11 Q2 & H1FY21: Branded Consumer Products Business Financial Highlights In INR Mn Revenue EBITDA & EBITDA Margin PAT & PAT Margin 109 12.3% 13.0% 9.1% 10.2% 14 11 41 5 4 Q2 FY21 H1 FY21 Q2 FY21 H1 FY21 Q2 FY21 H1 FY21
Slide 13: Company Overview
Page - 12 » Q2 & H1FY21 Result Highlights » Company Overview » Business Strategy » Industry & Outlook » Business Overview INVESTOR B A L A X I P H A R M A C E U T I C A LS L I M I T E D PRESENTATION COMPANY OVERVIEW
Slide 14: Vision Mission
Page - 13 Balaxi Pharmaceuticals: Bridging the supply chain gap in frontier markets B A L A X I P H A R M A C E U T I C A LS L I M I T E D We are a branded IPR-based pharmaceutical Company focusing on frontier markets, with a vast and growing portfolio of drugs across multiple therapeutic segments.
Slide 15: Values Purpose
Page - 14 Balaxi Pharmaceuticals: Bridging the supply chain gap in the frontier markets B A L A X I P H A R M A C E U T I C A LS L I M I T E D Our value system is the foundation for transparency and strong corporate governance. While we create value for shareowners, we work ethically and honestly to
Slide 16: Global Presence With Localisation
Page - 15 Balaxi Pharmaceuticals: Global Presence With Localisation B A L A X I P H A R M A C E U T I C A LS L I M I T E D A growing pharmaceutical company with on-ground presence in markets within Africa, Caribbean Islands & Latin America Headquartered in Hyderabad, India, we are an IPR-driven asse
Slide 17: The Company’s Evolution
Page - 16 Our Genesis: The Company’s Evolution B A L A X I P H A R M A C E U T I C A LS L I M I T E D Pre 2017 » The Company was listed on NSE in 2015 as ‘The Anandam Rubber Company Ltd’ 2017-2019 » In March, 2017, the Company was taken over by Balaxi Group, a prominent pharmaceuticals player in Ang
Slide 18: Balaxi Group’s Journey
Page - 17 Our Genesis: Balaxi Group’s Journey B A L A X I P H A R M A C E U T I C A LS L I M I T E D 2003-07 2008-10 2011-13 2014-16 2017-19 2020 » Commenced » Created front-end » Started sourcing » In 2014, the Group » Setup central » Submitted several Pharmaceutical presence for its pharmaceutical
Slide 19: Business Strategy
Page - 18 » Q2 & H1FY21 Result Highlights » Company Overview » Business Strategy » Industry & Outlook » Business Overview INVESTOR B A L A X I P H A R M A C E U T I C A LS L I M I T E D PRESENTATION BUSINESS STRATEGY
Slide 20: Our Approach For Creating Value
Page - 19 How We Operate: Our Approach For Creating Value B A L A X I P H A R M A C E U T I C A LS L I M I T E D 1 2 3 4 5 6 Intellectual Robust Product Asset-Light Geographical Focus on Brand Property Infrastructure & Registrations Production Footprint Equity Research Logistics » Balaxi undertakes
Slide 21: Straddling The Value Chain
Page - 20 How We Operate: Straddling The Value Chain B A L A X I P H A R M A C E U T I C A LS L I M I T E D Market & Product Selection We focus on bringing essential medicines within the reach of populations within frontier markets, which are challenging Market Research to penetrate. In particular,
Slide 22: Our Strengths “Built Over Time”
Page - 21 Balaxi’s Key Differentiators: Our Strengths “Built Over Time” B A L A X I P H A R M A C E U T I C A LS L I M I T E D Four ‘E’s differentiates BALAXI 1 Experience Two Decades of versatile experience of the BALAXI group ensures flawless execution. 18 years Entry into The Company enters a par
Slide 23: The making of a Pharmaceutical Major in multiple Frontier Markets
Page - 22 Investing In Balaxi: The making of a Pharmaceutical Major in multiple Frontier Markets B A L A X I P H A R M A C E U T I C A LS L I M I T E D » The Company participates in all stages of the pharma value chain, except in the R&D and manufacturing stages. Instead, it prefers to register prov
Slide 24: The making of a Pharmaceutical Major in multiple Frontier Markets (contd.)
Page - 23 Investing In Balaxi: The making of a Pharmaceutical Major in multiple Frontier Markets (contd.) B A L A X I P H A R M A C E U T I C A LS L I M I T E D 3 » The focus on the Company’s ‘cash & carry’ » The Company presently operates in three main regions Angola, Dominican model ensures regula
Slide 25: An Asset-Light Business Model Focussed on IPR’s
Page - 24 Balaxi Pharmaceuticals: An Asset-Light Business Model Focussed on IPR’s B A L A X I P H A R M A C E U T I C A LS L I M I T E D Pharmaceutical Industry Value Chain Balaxi’s Operating Areas Research & Drug Market Product Market & Pharmacy Registrations Manufacturing Development Discovery Res
Slide 26: Pharmaceuticals Business Overview
Page - 25 Pharmaceuticals Business Overview B A L A X I P H A R M A C E U T I C A LS L I M I T E D 36+% are Anitbiotic » The Company has a healthy ratio of branded and generic medicines in its portfolio of 24:76 (Branded: Generics). » The Company is in the business of supplying everyday medicines ad
Slide 27: Inherent Strategy Built Over Time Leading To Strong Brand Presence
Page - 26 Pharma Product Portfolio: Inherent Strategy Built Over Time Leading To Strong Brand Presence Geographical Mix % (Q2FY21) Geographical Mix % (H1FY21) • The Company generates 77% of the pharmaceutical revenue from Angola followed Dominican Republic and Guatemala. 8% 6% • The product split be
Slide 28: Product Mix & Categories 1/2
Page - 27 Pharma Product Portfolio: Product Mix & Categories 1/2 Product Mix % (Angola) Product Mix % (Guatemala) Product Mix % (Dominican Republic) 17% 12% 31% 69% 83% 88% Branded Generics Branded Generics Branded Generics Product Category Mix % (Angola) Product Category Mix % (Guatemala) Product C
Slide 29: Product Mix & Categories 2/2
Page - 28 Pharma Product Portfolio: Product Mix & Categories 2/2 Therapeutic Area % (Angola) Therapeutic Area % (Guatemala) Therapeutic Area % (Dominican Republic) 24% 31% 34% 41% 40% 0% 15% 61% 16% 12% 0% 26% Antibiotics Analgesic Anti Malaria Others Antibiotics Analgesic Anti Malaria Others Antibi
Slide 30: Glimpse of Our Products
Page - 29 Glimpse of Our Products B A L A X I P H A R M A C E U T I C A LS L I M I T E D
Slide 31: Adding New Geographies and Extensive Presence Through Robust On-Ground Infrastructure
Page - 30 “Our Land & Expand Strategy”: Adding New Geographies and Extensive Presence Through Robust B A L A X I P H A R M A C E U T I C A LS L I M I T E D On-Ground Infrastructure Our current established markets are Angola, Guatemala and Dominican Republic, where we have a strong presence in terms
Slide 32: Balaxi Pharmaceuticals Group Structure
Page - 31 Balaxi Pharmaceuticals Group Structure B A L A X I P H A R M A C E U T I C A LS L I M I T E D Balaxi Pharmaceuticals Limited Balaxi Global DMCC, Dubai (WOS) Balaxi Balaxi Balaxi Balaxi Balaxi Balaxi Balaxi Balaxi Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Slide 33: Industry & Outlook
Page - 32 » Q2 & H1FY21 Result Highlights » Company Overview » Business Strategy » Industry & Outlook » Business Overview INVESTOR B A L A X I P H A R M A C E U T I C A LS L I M I T E D PRESENTATION INDUSTRY & OUTLOOK
Slide 34: Macro Economy & Industry Data
Page - 33 New Geographies: Macro Economy & Industry Data • Central American countries reported US$ 825 million of pharmaceutical imports Macro Economic Data as on 2019 between January to March 2020. S&P Credit GDP Per GDP GDP Population Inflation Country Rating Capita (US$ bn) Growth % (mn) Rate % •
Slide 35: Enter, Expand and Excel
Page - 34 Future Roadmap: Enter, Expand and Excel B A L A X I P H A R M A C E U T I C A LS L I M I T E D The Company aims to establish its presence and expand in 20 frontier markets over the next 5 years. Balaxi In 2021-22 - Balaxi In 2020 Expansion In New – Business Geographies. Balaxi In 2023 & Co
Slide 36: Robust Pipeline Ahead
Page - 35 Pharma Products Registrations: Robust Pipeline Ahead Existing Registrations* Pipeline 548 Registrations as on date 580+ Registrations in Pipeline Angola comprises of 57% of 30+ Therapeutic segments 12 to 15 months timeline for Existing Registrations product registration after submitting te
Slide 37: Business Overview
Page - 36 » Q2 & H1FY21 Result Highlights » Company Overview » Business Strategy » Industry & Outlook » Business Overview INVESTOR B A L A X I P H A R M A C E U T I C A LS L I M I T E D PRESENTATION BUSINESS OVERVIEW
Slide 38: Leading Supplier Of Formulations in Angola, Guatemala and Dominican Republic
Page - 37 Pharmaceutical Business: Leading Supplier Of Formulations in Angola, Guatemala and B A L A X I P H A R M A C E U T I C A LS L I M I T E D Dominican Republic An IPR-driven pharma company with an asset-light, stock & sell model supplying branded & generic medicines in frontier markets. Angol
Slide 39: Leading Pharmaceutical Player in Angola
Page - 38 Pharmaceutical Business: Leading Pharmaceutical Player in Angola Industry Snapshot • Angola is the second largest oil producer in Africa with a population of ~32 million in 2019. • The GDP per capita on PPP basis is at US$ 6,644 in 2019. • Angola witnessed pharmaceutical imports worth US$
Slide 40: Leading Pharmaceutical Player in Guatemala
Page - 39 Pharmaceutical Business: Leading Pharmaceutical Player in Guatemala Industry Snapshot • Guatemala is part of the Latin American-Dominican Republic Free Trade Agreement (CAFTA-DR) which includes the United States and 6 Latin American countries. • Guatemala witnessed pharmaceutical imports w
Slide 41: Leading Pharmaceutical Player in Dominican Republic
Page - 40 Pharmaceutical Business: Leading Pharmaceutical Player in Dominican Republic Industry Snapshot • Dominican Republic is part of the Central American-Dominican Republic Free Trade Agreement (CAFTA- DR) which includes the United States and 6 Central American countries. • Dominican Republic wi
Slide 42: Encashing Our On-Ground Infrastructure
Page - 41 Ancillary Business: Encashing Our On-Ground Infrastructure Industry Snapshot • Angolan real estate market is largely dependent on state investments. • Property market continues to be seen as a safe-haven investment in the face of currency devaluation. • Builder’s Hardware is import depende
Slide 43: An Emerging Business
Page - 42 Branded Consumer Products: An Emerging Business Industry Snapshot • Angola is one of the most promising consumer-goods market in Africa. • Angola imports most of its consumer goods and utilities from countries such as Portugal, Brazil, China and South Africa. • The biscuits segment witness
Slide 44: Leadership Team
Page - 43 Strong Management: Leadership Team B A L A X I P H A R M A C E U T I C A LS L I M I T E D Ashish Maheshwari Pranav Maheshwari Paridhi Maheshwari Chairman & Managing Director Head – Latin America Head – Branded Consumer Products Founder of the company BBA and Economics Graduate from Emory B
Slide 45: Leadership Team
Page - 44 Strong Management: Leadership Team B A L A X I P H A R M A C E U T I C A LS L I M I T E D Ram Chawla Amol Mantri Country Head – Angola CFO Associated with the Balaxi Group since 2009 Qualified Chartered Accountant and Certified Public Accountant from USA Inherently talented in person to pe
Slide 46: Board of Directors
Page - 45 Strong Governance: Board of Directors B A L A X I P H A R M A C E U T I C A LS L I M I T E D Ashish Maheshwari Minoshi Maheshwari Chairman & Managing Director Non-Executive Director Founder of the company Co-Founder of the company First generation entrepreneur and a qualified A commerce gr
Slide 47: Board of Directors
Page - 46 Strong Governance: Board of Directors B A L A X I P H A R M A C E U T I C A LS L I M I T E D Kunal Bhakta Gandhi Gamji M.S Rao Rakesh Khanna Independent Director Independent Director Independent Director Independent Director A Chartered Accountant with 14 years of MBA and BE in Engineering
Slide 48: Thank You!
THANK YOU! B A L A X I P H A R M A C E U T I C A LS L I M I T E D Chinta Shalini Compliance Officer Email: secretarial@balaxi.in Aakash Mehta / Chintan Mehta IR Consultants - Dickenson World Contact No: +91 98706 79263/ 98921 83389 Email: balaxi@dickensonworld.com
Balaxi Pharmaceuticals — H1FY21 Earnings Presentation on 6ix